Merck: Aiming for Health Equity and Business Success

Josette Gbemudu is motivated to ensure everyone has the chance to be as healthy as possible

As an executive director of health equity and social determinants of health for Merck, Gbemudu draws on her health policy and public health backgrounds - and her strong moral compass and lived experience.

"I grew up in Nigeria and witnessed the health care and public health system crumble," she said. "Populations that were already underserved faced even further barriers to care."

She takes pride in giving a voice to those who may not traditionally have had a seat at the table.

"The work we do is very exciting and important - it's challenging, it's not easy, there's a lot you have to do to navigate - but it's all fulfilling," she said.

A ‘first mover'

Gbemudu is the first person from Merck to participate in the Aspen Institute's First Movers Fellowship program.

The program equips leaders across industries to be intrapreneurs, meaning they work to advance societal value while also positioning their companies for sustained success.

"The global community is increasingly asking, and frankly, requiring, organizations to have a clear position around what they are doing to tackle the world's most pressing and imminent challenges."
- Josette Gbemudu

"This fellowship has provided a tremendous opportunity to home in on what it takes to be a corporate social intrapreneur, and how to incorporate that intrapreneurial drive and mentality into my day-to-day," Gbemudu said.

At the nexus of health equity

Fellows are challenged to lead change and create new opportunities within their business to help redefine how business is done and how success is measured. At Merck, Gbemudu and her colleagues are developing and implementing company-wide strategies to help close gaps in care for underserved populations.

"It's fantastic to be at the nexus of the efforts to embed a health equity mindset across our core business strategies and functions," Gbemudu said. "Big problems won't be solved overnight. But historically, we've risen to the challenge in addressing a lot of pressing public health issues. It's interwoven into our DNA."

Learn more about Merck's Environmental, Social & Governance (ESG) approach by visiting merck.com/company-overview/esg.

View original content here.

View additional multimedia and more ESG storytelling from Merck & Co., Inc. on 3blmedia.com.

Contact Info:
Spokesperson: Merck & Co., Inc.
Website: https://www.3blmedia.com/profiles/merck-co-inc
Email: info@3blmedia.com

SOURCE: Merck & Co., Inc.



View source version on accesswire.com:
https://www.accesswire.com/748014/Merck-Aiming-for-Health-Equity-and-Business-Success

News Provided by ACCESSWIRE via QuoteMedia

MRK
The Conversation (0)
Raptor Resources

Eastern Metals Recommences ASX Trading – Aiming to Unlock High-Potential Copper Discoveries in New Brunswick, Canada

Eastern Metals Ltd (ASX: EMS) (Eastern Metals or the Company) (to be renamed Raptor Metals Ltd (ASX: RAP)) is pleased to advise it has recommenced trading on the Australian Securities Exchange (ASX) today following its acquisition of Raptor Resources Limited (Raptor Resources). HIGHLIGHTS... Keep Reading...
Merck Announces First-Quarter 2023 Financial Results

Merck Announces First-Quarter 2023 Financial Results

First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines Total Worldwide Sales Were $14.5 Billion, a Decrease of 9% From First Quarter 2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of... Keep Reading...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. , BELLUS Health Inc , Prometheus Biosciences, Inc. , Univar Solutions Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.... Keep Reading...

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health

Highlights: Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study. The Investigator Grant... Keep Reading...

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck (NYSE:MRK) reported quarterly worldwide sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and its full fiscal 2019 year. As quoted in the press release: As evidenced by our results and our 2020 guidance, Merck had an extraordinary year and is in a... Keep Reading...
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage... Keep Reading...
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...
Stacks of white pills progressively increase in height from left to right on a solid blue background.

Moderna, Merck Shares Soar on Cancer Vaccine Trial Success

An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19).The Phase 3 study evaluated the... Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...
US Food and Drug Administration website on a phone screen.

Eli Lilly Cancer Drug Wins FDA Breakthrough Therapy Status

The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Eli Lilly and Company's (NYSE:LLY) experimental drug olomorasib as a standalone treatment for patients with advanced pancreatic cancer and a KRAS G12C mutation who have received at least one systemic... Keep Reading...

Interactive Chart

Latest Press Releases

Related News